

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8541 - THERMO FISHER SCIENTIFIC / PATHEON

SECTION 1.2

Description of the concentration

On 15 May 2017, Thermo Fisher and Patheon announced that they had entered into a definitive agreement, under which Thermo Fisher will acquire all the outstanding ordinary shares of Patheon for US\$35.00 per share in cash, less any applicable withholding taxes and without interest, or approximately US\$7.2 billion (approximately €6.99 billion), including Patheon's net indebtedness.

Thermo Fisher is a manufacturer and supplier of laboratory equipment, analytical instruments, diagnostics and related products and services. It is headquartered in the United States and active internationally. Patheon is a contract development and manufacturing organisation, offering active pharmaceutical ingredient and finished drug product services, headquartered in The Netherlands and active internationally.